Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193401 | 1.00 | TDP1 (0.57) | TDP1MAOBSLC28A3SLC5A1SLC5A2 | |
| SCHEMBL7193412 | 0.93 | MAOB (0.54) | TDP1MAOBSLC28A3SLC5A1SLC5A2 | |
| SCHEMBL7184467 | 0.87 | SLC28A3 (0.51) | TDP1MAOBSLC28A3SLC5A1SLC5A2 | |
| SCHEMBL4652290 | 0.82 | SLC28A3 (0.55) | MAOBSLC28A3SLC5A1SLC5A2PTPN1 | |
| SCHEMBL30803061 | 0.78 | SLC28A3 (0.57) | SLC28A3SLC5A1SLC5A2HIF1A | |
| SCHEMBL940128 | 0.78 | TYR (0.50) | SLC28A3SLC5A1SLC5A2 | |
| SCHEMBL12610429 | 0.76 | SLC28A3 (0.55) | SLC28A3SLC5A1PTPN1HIF1A | |
| SCHEMBL30803032 | 0.76 | SLC28A3 (0.53) | SLC28A3SLC5A1SLC5A2HIF1A | |
| SCHEMBL12083356 | 0.75 | TDP1 (1.00) | TDP1 | |
| SCHEMBL4635870 | 0.75 | SLC28A3 (0.56) | SLC28A3SLC5A1SLC5A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
| EP-1859835-A2 | Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside | PENTAPHARM Ltd. (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20030198610-A1 | Topical agent for dermatological use | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | US | disclosed |
| EP-1289489-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM Ltd. (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001091715-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM LTD. (CH) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | GALE, ALPP, UGGT1 | TDP1 4401/4885MAOB 301/4885SLC28A3 2245/4885 |
| US-20030198610-A1 | Topical agent for dermatological use | GALE, UGGT1, UGDH | TDP1 4586/4885MAOB 304/4885SLC28A3 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.